Qualigen Therapeutics (QLGN)

• Market cap: $5.79M
• 1 day: -6.56%
• 5 days: -15.93%
• 1 month: -50.17%
• 3 months: 29.55%
• 6 months: -20.39%
• Year to date: -32.14%
• 1 year: -42.19%
• 5 years: -99.85%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: Qualigen Therapeutics Inc is an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's program, QN-302, is an investigational small-molecule G-quadruplexes (G4)-selective transcription inhibitor with binding affinity to G4s prevalent in cancer cells.

Employees: 4